Evidence map›Paper›PMID 34860468›Full record

SynthesisAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022

Effectiveness of T cell-mediated rejection therapy: A systematic review and meta-analysis.

Julie Ho, George N Okoli, Rasheda Rabbani, Otto L T Lam, Viraj K Reddy, Nicole Askin, Christie Rampersad, Aaron Trachtenberg, Chris Wiebe, Peter Nickerson and 1 more

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06474273 (A Multicenter Randomized Controlled Trial to Treat Acute t Cell Mediated Rejection in Kidney and Kidney-pancreas Transplant Recipients), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06474273 phase3recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicenter Randomized Controlled Trial to Treat Acute t Cell Mediated Rejection in Kidney and Kidney-pancreas Transplant Recipients

TypeinterventionalSponsorUniversity of SydneyRan2026 to 2030Enrolled540ConditionsRejection, Transplant, Kidney, Rejection, Transplant, PancreasArmsMethylprednisolone, Prednisone
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Effectiveness of T cell-mediated rejection therapy: A systematic review and meta-analysis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Biomarkers of Rejection in Kidney Transplantation.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Circulating T cell specific extracellular vesicle profiles in cardiac allograft acute cellular rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024
    Article
  17. The Banff 2022 Kidney Meeting Work Plan: Data-driven refinement of the Banff Classification for renal allografts.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024
    Article
  18. Article
  19. How to Treat T Cell Mediated Rejection? -A Call for Action.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  20. European Survey on Clinical Practice of Detecting and Treating T-Cell Mediated Kidney Transplant Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Julie HoDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-8342-9093
George N OkoliGeorge and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-6437-930X
Rasheda RabbaniGeorge and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-8830-4281
Otto L T LamGeorge and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0001-5803-6768
Viraj K ReddyGeorge and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-8526-4026
Nicole AskinNeil John Maclean Health Sciences Library, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0001-9211-4694
Christie RampersadDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0001-8040-7908
Aaron TrachtenbergDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0001-8940-5458
Chris WiebeDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-1006-3545
Peter NickersonDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-7393-7799
Ahmed M Abou-SettaGeorge and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0003-0153-9916

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effectiveness of T cell-mediated rejection (TCMR) therapy for achieving histological remission remains undefined in patients on modern immunosuppression. We systematically identified, critically appraised, and summarized the incidence and histological outcomes after TCMR treatment in patients on tacrolimus (Tac) and mycophenolic acid (MPA). English-language publications were searched in MEDLINE (Ovid), Embase (Ovid), Cochrane Central (Ovid), CINAHL (EBSCO), and Clinicaltrials.gov (NLM) up to January 2021. Study quality was assessed with the National Institutes of Health Study Quality Tool. We pooled results using an inverse variance, random-effects model and report the binomial proportions with associated 95% confidence intervals (95% CI). Statistical heterogeneity was explored using the I

Indexed as

Graft RejectionKidney TransplantationHumansImmunosuppressive AgentsMycophenolic AcidTacrolimusT-LymphocytesImmunosuppressive AgentsMycophenolic AcidTacrolimusclinical research/practicegraft survivalimmunosuppression/immune modulationimmunosuppressive regimenskidney (allograft) function/dysfunctionkidney transplantation/nephrologyrejection: antibody-mediated (ABMR)rejection: T cell mediated (TCMR)

Identifiers

PMID34860468
PMCPMC9300092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.